Intravitreal injection of anti-VEGF has revolutionized the management and visual prognosis for patients with AMD, diabetic macular edema, and other diseases, resulting in retinal vascular leakage or choroidal neovascularization. The gene discussed is VEGFA; the disease is diabetic macular edema.